Indomethacin augments lipopolysaccharide-induced expression of inflammatory molecules in the mouse brain
Author and article information
Abstract
Indomethacin and other non-steroidal anti-inflammatory drugs (NSAIDs) are used to relieve pain and fever including during infections. However, some studies suggest that NSAIDs protect against neuroinflammation, while some find no effects or worsening of neuroinflammation. We evaluated the effect of indomethacin alone on in combination with minocycline, a drug that inhibits neuroinflammation, on the expression of transcripts of neuroinflammatory molecules-induced by lipopolysaccharide (LPS) in the brain of mice. Inoculation of male BALB/c mice with LPS induced the expression of the microglia marker ionized calcium binding adaptor molecule protein, mRNA expression of the genes for cytokines interleukin-1beta (Il1b) and tumor necrosis factor-alpha (Tnf) and inducible nitric oxide synthase gene (Nos2), but not Il10, in the brain. Treatment with indomethacin had no significant effect on the cytokines or Nos2 mRNA expression in naïve animals. However, pretreatment with indomethacin increased LPS-induced Nos2 mRNA and inducible nitric oxide (iNOS) protein expression, but had no significant effect on LPS-induced mRNA expression of the cytokines. Minocycline reduced LPS-induced Il1b and Tnf, but not Nos2, mRNA expression. Treatment with indomethacin plus minocycline had no effect on LPS-induced Il1b, Tnf and Nos2 mRNA expression. In conclusion these results show that indomethacin significantly augments LPS-induced Nos2 mRNA and iNOS protein expression in the brain. In the presence of indomethacin, minocycline could not inhibit LPS-induced pro-inflammatory cytokine expression. Thus, indomethacin could exacerbate neuroinflammation by increasing the expression of iNOS and also block the anti-inflammatory effects of minocycline.
Cite this as
2020. Indomethacin augments lipopolysaccharide-induced expression of inflammatory molecules in the mouse brain. PeerJ 8:e10391 https://doi.org/10.7717/peerj.10391Main article text
Introduction
Neuroinflammation is one of the features shared by a lot of neurodegenerative diseases and infectious diseases (Chen, Zhang & Huang, 2016; Guo & Buch, 2019; Masocha & Parvathy, 2009; Meneses et al., 2019; Molteni & Rossetti, 2017; Schain & Kreisl, 2017). Some of its features include microglia activation. Activated microglia undergo morphological changes into amoeboid form accompanied with changes in their gene expression pattern. Activated microglia increase the expression of different mediators such as tumor necrosis factor (TNF-α), interleukin-1 beta (IL-1β), IL-12, reactive oxygen species (ROS), nitric oxide (NO), prostaglandins and chemokines, which start a cascade of immune reaction to the site of inflammation aimed at destroying the invading pathogen or dead cell but can also cause neuronal damage (Loane & Byrnes, 2010; Lull & Block, 2010; Wolf, Boddeke & Kettenmann, 2017).
Microglia can be activated by several pro-inflammatory stimuli such as lipopolysaccharide (LPS), an endotoxin obtained from the Gram-negative bacteria’s outer membrane surface. Lipopolysaccharide induces cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS) and pro-inflammatory cytokine expression in the brain (Biesmans et al., 2013; Catorce & Gevorkian, 2016; Edan, Luqmani & Masocha, 2013; Qin et al., 2007). Treating cell cultures or animals with LPS has been used to activate microglia and to study the effect of anti-inflammatory drugs on neuroinflammation (Edan, Luqmani & Masocha, 2013; Fan et al., 2005; Henry et al., 2008; Hoogland et al., 2015; Kim et al., 2004).
Indomethacin, a non-steroidal anti-inflammatory drug (NSAID), is mainly used for treatment of pain, inflammation, and fever in several chronic inflammatory diseases (Eccleston et al., 2017; Nalamachu & Wortmann, 2014). In terms of neuroinflammation, indomethacin and other NSAIDs have been reported to have different effects on LPS-induced microglia activation and pro-inflammatory molecule expression; that is, inhibition, no effect and augmentation of LPS-induced neuroinflammatory effects (Aid, Langenbach & Bosetti, 2008; Banks et al., 2015; Blais, Turrin & Rivest, 2005; Na et al., 2015; Nakamori et al., 1994; Sacco et al., 1998; Teeling et al., 2007).
In this study, we evaluated the LPS-induced neuroinflammation in the brain by measuring the expression of the microglia marker ionized calcium binding adaptor molecule (Iba-1) protein, the transcripts of the genes of pro-inflammatory molecules that is, the cytokines interleukin 10 (Il10), Il1b and tumor necrosis factor-alpha (Tnf) and as well as the inducible nitric oxide synthase 2 (Nos2). We evaluated the effects of pretreatment with indomethacin on LPS-induced expression of the transcripts of Il10, Il1b, Tnf and Nos2, as well as the iNOS protein. We also evaluated the effects of pretreatment with indomethacin plus minocycline, a drug that inhibits neuroinflammation (Guo & Bhat, 2007; Henry et al., 2008; Hou et al., 2016; Plane et al., 2010; Stirling et al., 2005; Tikka et al., 2002; Yrjänheikki et al., 1998), on LPS-induced expression of the transcripts of Il1b, Tnf and Nos2.
Materials and Methods
Animals, LPS administration and drug treatment
One hundred and ten male BALB/c mice (8–12 weeks old; 20–30 g) provided by the breeding unit at the Health Science Center, Kuwait University were used in this study. Animals were kept in temperature controlled (24 ± 1 °C) rooms on a 12-h light/dark cycle and constantly checked for signs of disease. All animals were provided with standard food and water ad libitum. All animal experiments were approved by the Ethical Committee for use of Laboratory Animals in Teaching and Research of the Health Sciences of Kuwait University.
All the drugs were administered at a volume of 10 ml/kg body mass.
The first group of mice (n = 16) either received a single intraperitoneal (i.p.) dose of LPS from Escherichia coli (strain O111:B4, Sigma–Aldrich, St. Louis, MO, USA, n = 8) 1 mg/kg or its solvent (phosphate buffered saline, PBS, n = 8). The dose of LPS was selected based on those previously shown to induce microglia activation and cytokine expression (Edan, Luqmani & Masocha, 2013).
In the second group (n = 8), mice were either treated daily for 3 days with indomethacin 10 mg/kg (Sigma–Aldrich, St. Louis, MO, USA, n = 4) dissolved in peanut oil or with its vehicle (n = 4), and sacrificed 4 h after the last dose of indomethacin. The dose of indomethacin used in this study is based on that reported to alleviate LPS-induced arthritis (Masocha & Parvathy, 2009).
In the third group, 30 mice were divided into three treatment groups (untreated control, vehicle plus LPS, and indomethacin plus LPS, n = 10 per group) and treated i.p. daily for 3 days with indomethacin 10 mg/kg (Sigma–Aldrich, St. Louis, MO, USA) or its vehicle, commencing 2 days before LPS inoculation. On the third day after drug treatment the mice were inoculated with either LPS or its vehicle and sacrificed after 4 h.
In the fourth group, 24 mice were divided into three treatment groups (untreated control, vehicle plus LPS, and minocycline plus LPS, n = 8 per group) and treated i.p. daily for 3 days with minocycline 50 mg/kg (Sigma–Aldrich, St. Louis, MO, USA) dissolved in PBS or its vehicle, commencing 2 days before LPS inoculation. On the third day after drug treatment the mice were inoculated with either LPS or its vehicle and sacrificed after 4 h. The dose of minocycline used in this study is based on that reported to inhibit LPS-induced microglia activation (Henry et al., 2008).
In the fifth group, 32 mice were divided into three treatment groups (untreated control (n = 9), vehicle plus LPS (n = 9), and indomethacin plus minocycline plus LPS (n = 14)) and treated i.p. daily for 3 days with indomethacin plus minocycline or their vehicles, commencing 2 days before LPS inoculation. On the third day after drug treatment the mice were inoculated with either LPS or its vehicle and sacrificed after 4 h.
On the last day of drug treatment and LPS inoculation mice were deeply anaesthetized with halothane, sacrificed by decapitation, brains removed and dissected out, snap frozen in liquid nitrogen and kept at −70 °C until protein or mRNA extraction.
Wes™ capillary-based protein electrophoresis
The protein expression of Iba-1 and iNOS was measured using the automated Wes™ capillary-based protein electrophoresis (ProteinSimple, San Jose, CA, USA) and the 12–230 kDa separation module following the manufacturer’s user guide as described previously (Aly, Khajah & Masocha, 2020). Briefly, half of the fresh frozen brains were homogenized, and protein concentrations determined as described previously (Aly, Khajah & Masocha, 2020). Brain homogenates were diluted to 1 mg/mL using 0.1X buffer. Four parts of the sample was mixed with one part of 5X fluorescent mix, followed by denaturation at 95 °C for 5 min. The primary antibodies for rabbit anti-Iba-1 (Boster Bio, Pleasanton, CA, USA), mouse monoclonal anti-iNOS (OriGene Technologies, Rockville, MD, USA), and rabbit anti-β-actin (Cell Signaling, Danvers, MA, USA; housekeeping protein) were diluted in a ratio of 1:50, using the antibody diluent. The secondary anti-rabbit and anti-mouse antibodies were supplied with the kits (ProteinSimple, San Jose, CA, USA). The assay plate was loaded following the manufacturer’s user guide and centrifuged at 2,500 rpm for 5 min at room temperature. The plate and the capillaries were loaded onto the automated Wes instrument for electrophoresis and immunodetection. At the end of the run data generated were analyzed using the Compass for Simple Western software (ProteinSimple, San Jose, CA, USA). The ratio between of the areas of the resulting electropherograms for Iba-1 and β-actin were calculated (as shown in Fig. S1).
Real time RT-PCR
Expression of Il10, Il1b, Tnf and Nos2 mRNA was quantified relative to the expression of the house keeping gene Ppia (cyclophilin A) using real time PCR. Total RNA was extracted from half of the fresh frozen brains, reverse-transcribed into cDNA and real time PCR performed on an ABI Prism® 7500 sequence detection system (Applied Biosystems) as described previously (Masocha, 2009). The primers for Ppia, Il10, Il1b, Tnf and Nos2 were purchased from Invitrogen Life Technologies. The primer sequences are listed in Table 1. The threshold cycle (Ct) values for all cDNA samples were obtained and the level of mRNA for each sample were normalized to Ppia (housekeeping gene) ΔCt. The relative expression of the gene of interest was calculated using −2−ΔΔCt method using the following equations (Livak & Schmittgen, 2001).
| Gene | Polarity | Sequence 5′–3′ | GenBank* |
|---|---|---|---|
|
Ppia (cyclophilin A) |
Sense Anti-sense |
GCTTTTCGCCGCTTGCT CTCGTCATCGGCCGTGAT |
X52803 |
|
Tnf (tumor necrosis factor alpha) |
Sense Anti-sense |
GGCTGCCCCGACTACGT GACTTTCTCCTGGTATGAGATAGCAAA |
NM-013693 |
|
Il10 (interleukin 10) |
Sense Anti-sense |
CAGCCGGGAAGACAATAACTG CCGCAGCTCTAGGAGCATGT |
NM-010548 |
|
Il1b (interleukin 1 beta) |
Sense Anti-sense |
TGGTGTGTGACGTTCCCATT CAGCACGAGGCTTTTTTGTTG |
NM-008361 |
|
Nos2 (nitric oxide synthase 2) |
Sense Anti-sense |
AACATCAGGTCGGCCATCA CGTACCGGATGAGCTGTTGAA |
M84373 |
Note:
Statistical analyses
Data were tested for normality using the D’Agostino-Pearson normality test; if data passed the normality test, that is, were normally distributed, parametric tests were used, however, if they failed the normality test, that is, were not normally distributed, non-parametric tests were used. Further statistical analysis was performed using Student’s t test, one-way analysis of variance (ANOVA) followed by Tukey multiple comparison test for normally distributed data and Mann–Whitney U test or Kruskal–Wallis test followed by Dunn’s multiple comparison test for non-normal data using GraphPad Prism software (version 6.0). The differences were considered significant at p < 0.05. The results in the text and figures are expressed either as the mean ± SEM or a median and interquartile range.
Results
Effect of LPS on expression of proinflammatory and anti-inflammatory molecules in the brain
Lipopolysaccharide induced the protein expression of the microglia marker Iba-1 and increased mRNA of the proinflammatory molecules Il1b, Tnf and Nos2, but had no effect on the mRNA of the anti-inflammatory cytokine Il10, in the brains of mice compared to vehicle treatment (Figs. S2 and S3).
Effect of indomethacin on Il10, Il1b, Tnf and Nos2 mRNA expression
Treatment with indomethacin had no significant effect on Il10, Il1b, Tnf and Nos2 mRNA in the brains of mice compared to vehicle treatment. The Mann–Whitney U test showed there was no difference in the mRNA of Il10, Il1b, Tnf and Nos2 between the brains of mice treated with indomethacin compared to vehicle-treated control mice (U = 2, p = 0. 0.1143; U = 1, p = 0.0571; U = 5, p = 0.4857; U = 3, p = 0. 0.4857, respectively; Fig. 1). However, there was a trend to increase the mRNA of Il1b (median of relative expression 2.269) and to decrease the mRNA of Il10 (median of relative expression 0.4671) in the brains of mice treated with indomethacin compared to vehicle-treated control mice.
Figure 1: Effect of treatment of BALB/c mice with indomethacin on Il10, Il1b, Tnf and Nos2 mRNA expression.
Relative expression of (A) Il10, (B) Il1b, (C) Tnf and (D) Nos2 mRNA in the brain of control (vehicle-only) and indomethacin-treated mice. Each box and whiskers represent the median and interquartile range of the values obtained from four animals. There was no statistically significant difference with vehicle-treated control animals (Mann–Whitney U test).Effects of treatment with indomethacin on LPS-induced changes of Il10, Il1b, Tnf and Nos2 mRNA expression
Treatment with indomethacin had no significant effect on LPS-induced Il1b and Tnf mRNA, but significantly increased Nos2 mRNA (Fig. 2). For l10 mRNA, a Kruskal–Wallis test showed that there was no statistically significant difference in transcript levels between the treatment groups (H(2) = 4.74, p = 0.0921; Fig. 2A). For l1b and Tnf mRNA, a Kruskal–Wallis test showed that there was a statistically significant difference in transcript levels between the treatment groups (H(2) = 21.24, p < 0.0001; H(2) = 22.17, p < 0.0001, respectively). However, a Dunn post-hoc test showed that there was no difference in the relative expression of Il1b and Tnf mRNA between the brains of LPS-inoculated mice treated with indomethacin and those of LPS-inoculated mice treated with vehicle (p > 0.05; Figs. 2B and 2C). For Nos2 mRNA there was a statistically significant difference between the treatment groups as determined by one-way ANOVA (F(2, 27) = 8.247, p = 0.0016). A Tukey post-hoc test showed that the brain of LPS-inoculated mice treated with indomethacin had significantly higher relative expression of Nos2 mRNA compared to of LPS-inoculated mice treated with vehicle (p < 0.05; Fig. 2D).
Figure 2: Effect of treatment with indomethacin on LPS-induced changes of Il10, Il1b, Tnf and Nos2 mRNA expression.
Relative expression of (A) Il10, (B) Il1b, (C) Tnf and (D) Nos2 mRNA in the brains of uninoculated control, LPS-inoculated vehicle-treated and LPS-inoculated indomethacin-treated mice at 4 h post inoculation. Each bar or box and whiskers represents the mean ± the SEM (C) or median and interquartile range (A and B), respectively, of the values obtained from ten animals. **p < 0.01, ***p < 0.001 compared to vehicle-treated control, and #p < 0.05 compared to mice inoculated with LPS (one-way ANOVA followed by Tukey multiple comparison test for Nos2 or Kruskal–Wallis test followed by Dunn’s multiple comparison test for Il10, Il1b and Tnf).Effects of treatment with indomethacin on LPS-induced changes of iNOS protein expression
There was a significant increase in iNOS protein expression in the brain of LPS-inoculated mice treated with indomethacin, but not vehicle, compared to uninoculated control mice (Fig. 3). There was a statistically significant difference in iNOS protein levels between the treatment groups as determined by Kruskal–Wallis test (H(2) = 8.778, p = 0.0075). A Dunn post-hoc test showed that the brain of LPS-inoculated mice treated with indomethacin had significantly higher relative expression of iNOS protein compared to the brain of uninoculated mice treated with vehicle, but not LPS-inoculated mice treated with vehicle (p < 0.05; p > 0.05, respectively; Fig. 3).
Figure 3: Effect of treatment with indomethacin followed by LPS-induced inoculation on iNOS protein expression.
Protein expression of iNOS in the brains of uninoculated control, LPS-inoculated vehicle-treated and LPS-inoculated indomethacin-treated mice at 4 h post inoculation. Each box and whiskers represents the median and interquartile range of the values obtained from six to eight animals. The dot above the control shows an outlier value. *p < 0.05 compared to vehicle-treated control (Kruskal–Wallis test followed by Dunn’s multiple comparison test).Effects of treatment with minocycline alone or with indomethacin on LPS-induced changes of Il1b, Tnf and Nos2 mRNA expression
Treatment with minocycline markedly reduced LPS-induced Il1b and Tnf mRNA, but not Nos2 mRNA (Figs. 4A–4C). For Il1b and Tnf mRNA there was a statistically significant difference between the treatment groups as determined by one-way ANOVA (F(2, 21) = 38.36, F(2, 21) = 69.77, respectively, p < 0.0001). A Tukey post-hoc test showed that the brain of LPS-inoculated mice treated with minocycline had significantly lower relative expression of Il1b and Tnf mRNA compared to LPS-inoculated mice treated with vehicle (p < 0.001; Figs. 4A and 4B). For Nos2 mRNA, a Kruskal–Wallis test showed that there was a statistically significant difference in transcript levels between the treatment groups (H(2) = 15.61, p = 0.0004). However, a Dunn post-hoc test showed that there was no difference in the relative expression of Nos2 mRNA between the brains of LPS-inoculated mice treated with minocycline and those of LPS-inoculated mice treated with vehicle (p > 0.05; Fig. 4C).
Figure 4: Effect of treatment with minocycline or co-treatment with indomethacin plus minocycline on LPS-induced upregulation of Il1b, Tnf and Nos2 mRNA expression.
Relative expression of (A) Il1b, (B) Tnf and (C) Nos2 mRNA in the brains of uninoculated control, LPS-inoculated vehicle-treated and LPS-inoculated minocycline-treated mice at 4 h post inoculation. Each bar represents the mean ± the SEM (A and B) or median and interquartile range (C) of the values obtained from eight animals. Relative expression of (D) Il1b, (E) Tnf and (F) Nos2 mRNA in the brains of uninoculated control, LPS-inoculated vehicle-treated and LPS-inoculated indomethacin plus minocycline-treated mice at 4 h post inoculation. Each bar represents the median and interquartile range of the values obtained from nine to fourteen animals. *p < 0.05, **p < 0.01, ***p < 0.001 compared to vehicle-treated control, and ###p < 0.001 compared to mice inoculated with LPS (one-way ANOVA followed by Tukey multiple comparison test for (A) and (B) or Kruskal–Wallis test followed by Dunn’s multiple comparison test for (C–F).Co-administration of indomethacin with minocycline had no significant effect on LPS-induced Il1b, Tnf and Nos2 mRNA (Figs. 4D–4F). A Kruskal–Wallis test showed that there was a statistically significant difference in Il1b, Tnf and Nos2 mRNA expression between the treatment groups (H(2) = 18.82, p < 0.0001; H(2) = 19.03, p < 0.0001; H(2) = 18.18, p < 0.0001, respectively). However, a Dunn post-hoc test showed that there was no difference in the relative expression of Il1b, Tnf and Nos2 mRNA between the brains of LPS-inoculated mice co-treated with indomethacin plus minocycline and those of LPS-inoculated mice treated with vehicle (p > 0.05; Figs. 4D–4F).
Discussion
Systemic administration of LPS has been shown activate microglia and induce neuroinflammation including induction of the expression of the proinflammatory cytokines, Nos2 and iNOS (Czapski et al., 2007; Edan, Luqmani & Masocha, 2013; Hom et al., 1995; Jacobs et al., 1997; Qin et al., 2007). Therefore, bacterial LPS has been used in models studying neuroinflammation and evaluating drugs that can inhibit neuroinflammation (Edan, Luqmani & Masocha, 2013; Henry et al., 2008; Iliev et al., 2001; Marchalant, Rosi & Wenk, 2007). In the current study, LPS increased the protein expression of the microglia marker Iba-1 and transcript levels of Nos2 and the proinflammatory cytokines Il1b and Tnf, but had no effect on the transcript levels of the anti-inflammatory cytokine Il10, in the brain. Treatment with indomethacin had no significant effects in the transcripts of the cytokines Il10, Il1b and Tnf and Nos2 transcripts in the brains of naïve animals. Treatment with indomethacin enhanced the LPS-induced elevation in the transcripts of Nos2, but not the cytokines Il10, Il1b and Tnf transcripts. Indomethacin also caused an increased expression of iNOS in the brains of LPS-inoculated mice, whereas LPS on its own did not, compared to uninoculated vehicle-treated mice brains. Treatment with minocycline inhibited the LPS-induced elevation in the transcripts of the cytokines Il1b and Tnf, but not Nos2 transcripts. However, in the presence of indomethacin, minocycline lost its inhibitory effects on LPS-induced elevation in the transcripts of the cytokines that is, co-treatment with indomethacin plus minocycline had no effect on the LPS-induced elevation in the transcripts of the cytokines (Il1b and Tnf) and Nos2.
Microglia are a well-known source of proinflammatory cytokines (Conti et al., 2020; Giulian & Baker, 1986; Sawada et al., 1989; Smith et al., 2012; Xu, He & Bai, 2016). Based on that, the upregulation of Iba-1 protein expression as an indicator of microglia activation (Huang et al., 2008; Ito et al., 1998; Ito et al., 2001) in the brains of LPS-inoculated animal was investigated. Iba-1 protein was upregulated in the brain after LPS inoculation, which confirmed the activation of microglia, similar to what has been reported in other studies using western blot or immunohistochemistry techniques (Hoogland et al., 2015; Hu et al., 2011; Reinert et al., 2014).
Inoculation with LPS increased Tnf, Il1b and Nos2 mRNA, but did not affect Il10 mRNA in the brain of BALB/c mice. These findings of LPS-induced increase in the levels of proinflammatory cytokine transcripts (Tnf and Il1b) agree with several previous studies (Edan, Luqmani & Masocha, 2013; Layé et al., 1994; Murray, Skelly & Cunningham, 2011; Qin et al., 2007). In the current study LPS did not alter the expression of IL-10 transcripts similar to a previous study (Szot et al., 2017). However, some studies have shown that LPS increases IL-10 transcripts in the brain (Yang et al., 2020; Neupane et al., 2018). The findings of LPS-induced increase in the levels of Nos2 transcripts in the brain are also in agreement with previous studies (Murray, Skelly & Cunningham, 2011; Voronova et al., 2016). Thus, the current data correlate with the previous reported findings that LPS-induced proinflammatory cytokines and Nos2 expression, which elicit an inflammatory response in the brain.
Currently, NSAIDs, which produce their effects via inhibition of COX activity and consequently prostaglandin (PG) synthesis, are one of the main drugs used to relieve pain in many chronic inflammatory diseases, such as rheumatoid arthritis (Hussain et al., 2012). However, the exact role of COX inhibition in systemic inflammation caused by LPS and their effect on neuroinflammation remains controversial. A previous study showed that the NSAID indomethacin can reverse LPS-induced behavioral changes including sickness without changing peripheral or central increase of Il1b and Tnf mRNA levels (Teeling et al., 2007). However, another study showed that COX-2–deficient mice showed a higher increase in Nos2, Tnf and Il1b gene expression and iNOS, TNF-α and IL-1β protein levels after LPS inoculation when compared to normal mice, which increased their susceptibility to LPS-induced damage (Aid, Langenbach & Bosetti, 2008). This study by Aid, Langenbach & Bosetti (2008) and our study agree with another study that showed that indomethacin, a COX inhibitor, increased the inflammatory response in the brain after systemic LPS administration (Blais, Turrin & Rivest, 2005). On the other hand, the current study revealed that indomethacin had no significant effect on LPS-induced elevation in cytokine transcripts, similar to what was reported previously (Teeling et al., 2007). Previous studies have reported different effects of indomethacin on LPS-induced increase in IL-1 β and TNF-α protein in the brain that is, in some studies it had no effects on LPS-induced increase in IL-1 β and TNF-α protein in the brain (Nakamori et al., 1994; Sacco et al., 1998), whereas in another study it inhibited the LPS-induced increase in IL-1 β protein but had no effect on TNF-α protein in the brain (Banks et al., 2015). In the current study, indomethacin significantly increased the LPS-induced elevation in Nos2 transcripts and pretreatment with indomethacin before LPS increased iNOS protein levels when LPS alone did not, which is agreement to the study by Aid et al that COX-2 inhibition or deletion increases Nos2 transcripts and iNOS protein expression when LPS is inoculated (Aid, Langenbach & Bosetti, 2008). On the other hand, various previous studies have reported that indomethacin inhibits LPS-induced increase in Nos2 transcripts and iNOS protein in macrophages cell culture and rat cerebellum (Aeberhard et al., 1995; Di Girolamo et al., 2003; Pang & Hoult, 1996). The difference between the effects of indomethacin on LPS-induced elevation in Nos2 transcripts in the current study and that of DiGirolamo and colleagues (Di Girolamo et al., 2003) could be due the difference in animal species used that is, mice versus rats or the number of doses that is, three doses over three days compared to a single dose. Repeated or chronic administration of indomethacin has been shown to cause microglia activation or enhance LPS-induced inflammation (Na et al., 2015; Prechel et al., 2000). Various studies investigating the role of NSAIDs in treating neurodegenerative diseases have produced conflicting results. In a randomized clinical trial, indomethacin was shown to protect Alzheimer’s disease (AD) patients by having a slower degree of cognitive decline when compared to those on placebo (Rogers et al., 1993). However, the positive result is difficult to interpret because 42% of the patients abandoned the study due to adverse events. Another study, a double blinded clinical trial, showed that indomethacin did not slow the progression of AD (De Jong et al., 2008). The findings of the current study show that indomethacin, or inhibition of COX enzymes, is proinflammatory rather that anti-inflammatory in the CNS during LPS-induced neuroinflammation.
Minocycline significantly reduced LPS-induced elevation in the transcripts of Tnf and Il1b, similar to what has been reported previously (Henry et al., 2008; Hou et al., 2016; Tomás-Camardiel et al., 2004). These findings support the notion of that minocycline has anti-inflammatory effect and ameliorates neuroinflammation. However, minocycline had no effect on LPS-induced increase of Nos2 mRNA expression in the brain, similar to what reported previously (Tomás-Camardiel et al., 2004). This is contrary to previous in vitro studies, which showed that minocycline inhibited LPS-induced elevation of Nos2 mRNA and NO production in cultured retinal microglial cells (Lee et al., 2004). The discrepancy could be due to the fact in vitro there were only microglia cells, whereas in vivo there are other cells and molecules that can influence the effect of minocycline.
In the current study, co-treatment with indomethacin plus minocycline had no significant effect on the LPS-induced elevation in Il1b and Tnf transcripts. These results suggest that, the beneficial effect of minocycline in reducing the LPS-induced expression of the proinflammatory cytokines Tnf and Il1b transcripts found in this study were annulled by indomethacin. Co-treatment with indomethacin plus minocycline also had no significant effect on LPS-induced elevated levels of Nos2 transcripts. These results suggest that minocycline protected against the indomethacin-induced worsening of LPS effects. The results of the current study suggest that although minocycline blocks indomethacin augmentation of LPS-induced elevation in Nos2 transcripts, it loses its beneficial effects of reducing LPS-induced proinflammatory cytokine expression.
Conclusions
In conclusion, the results of this study show that indomethacin augments the LPS-induced elevation in Nos2 transcripts levels in the brain, induces elevation of iNOS proteins in combination with LPS, whereas LPS on its own did not. However, indomethacin had no significant effects on cytokine transcripts on its own or on LPS-induced elevation in transcripts of proinflammatory cytokines in the brain. Minocycline protects against LPS-induced elevation in proinflammatory cytokine transcripts and co-treatment with indomethacin plus minocycline had no effect on LPS-induced elevation in transcripts of proinflammatory cytokines in the brain. Thus, treatment with indomethacin could worsen neuroinflammation via increased iNOS both at gene and protein expression levels. In addition, minocycline’s anti-neuroinflammatory effects are annulled in the presence of indomethacin.
Supplemental Information
Relative expression of Il10, Il1b, Tnf and Nos2 mRNA in the brain of control (vehicle-only ), LPS-inoculated vehicle-treated and LPS-inoculated indomethacin-treated at 4 h post LPS/vehicle inoculation.
Expression of Iba-1 protein in the brain of control (vehicle-only) and LPS-inoculated mice at 4 h post LPS/vehicle inoculation.
Relative expression of Il10, Il1b, Tnf and Nos2 mRNA in the brain of control (vehicle-only ), LPS-inoculated vehicle-treated and LPS-inoculated indomethacin plus minocycline-treated at 4 h post LPS/vehicle inoculation.
Relative expression of Il10, Il1b, Tnf and Nos2 mRNA in the brain of control (vehicle-only ), LPS-inoculated vehicle-treated and LPS-inoculated indomethacin plus minocycline-treated at 4 h post LPS/vehicle inoculation.
Relative expression of Il1b, Tnf and Nos2 mRNA in the brain of control (vehicle-only) and LPS-inoculated mice at 4 h post LPS/vehicle inoculation.
Expression of iNOS protein in the brain of control (vehicle-only), LPS-inoculated vehicle-treated and LPS-inoculated indomethacin-treated at 4 h post LPS/vehicle inoculation.
Relative expression of Il10, Il1b, Tnf and Nos2 mRNA in the brain of control (vehicle-only ), LPS-inoculated vehicle-treated and LPS-inoculated minocycline-treated at 4 h post LPS/vehicle inoculation.
Relative expression of Il1b, Tnf and Nos2 mRNA in the brain of control (vehicle-only) and indomethacin-treated mice at 4 h post treatement.
Virtual-blot like image similar to traditional results obtained from electropherograms for Figure 1.
Lane 1 and 2 is for actin, lane 3 and 4 is for Iba-1
Illustration of Wes™ data analysis.
Data analysis using ratio the between of the areas of the resulting electropherograms for Iba-1 and β-actin generated during the Wes™ capillary-based protein electrophoresis.
Effect of inoculation of BALB/c mice with lipopolysaccharide (LPS) on Iba-1 protein expression.
Protein expression of Iba-1 in the brain of control (vehicle-only) and LPS-inoculated mice at 4 h post LPS/vehicle inoculation. Each box and whiskers represents the median and interquartile range of the values obtained from five animals. Statistically significant difference with vehicle-treated control animals: **p < 0.01 (Mann–Whitney U test).
Effect of inoculation of BALB/c mice with lipopolysaccharide (LPS) on Il10, Il1b, Tnf and Nos2 mRNA expression.
Relative expression of (A) Il10, (B) Il1b, (C) Tnf and (D) Nos2 mRNA in the brain of control (vehicle-only) and LPS-inoculated mice at 4 h post LPS/vehicle inoculation. Each bar or box and whiskers represents the mean ± S.E.M (A and B) or median and interquartile range (C), respectively, of the values obtained from eight animals. Statistically significant difference with vehicle-treated control animals: ***p < 0.01 (Student’s t test for Il10, Il1b and Tnf or Mann–Whitney U test for Nos2).
Additional Information and Declarations
Competing Interests
The authors declare that they have no competing interests.
Author Contributions
Mona Yasin Mohamed performed the experiments, analyzed the data, prepared figures and/or tables, and approved the final draft.
Willias Masocha conceived and designed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
Animal Ethics
The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):
The Ethical Committee for Use of Laboratory Animals in Teaching and Research of the Health Sciences of Kuwait University approved this research.
Data Availability
The following information was supplied regarding data availability:
The protein expression raw data and real-time PCR raw data are available in the Supplemental Files.
The protein expression was done using the ProteinSimple’s WesTM Capillary-Based Protein Electrophoresis; thus, the raw data comes as electropherograms from which virtual-blot-like images similar to traditional results as well as a Supplemental File showing the height and area under the electropherograms are generated.
Funding
This study was supported by grant YP 01/18 from Kuwait University Research Sector and the Core Research Facility KU project # OMICSRU/RCF project SRUL02/13 for the real-time PCR equipment. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
